Aurora Cannabis (TSE:ACB) Price Target Cut to C$3.00 by Analysts at Stifel Nicolaus

Aurora Cannabis (TSE:ACBGet Rating) had its target price cut by research analysts at Stifel Nicolaus from C$3.50 to C$3.00 in a research report issued on Monday, BayStreet.CA reports. Stifel Nicolaus’ target price suggests a potential downside of 22.28% from the company’s current price.

A number of other equities research analysts also recently weighed in on the stock. Cowen cut their price target on shares of Aurora Cannabis from C$10.00 to C$7.00 and set a “neutral” rating for the company in a report on Friday, February 11th. Canaccord Genuity Group cut their price target on shares of Aurora Cannabis from C$6.00 to C$5.00 in a report on Friday, February 11th. CIBC cut their price target on shares of Aurora Cannabis from C$9.25 to C$6.50 in a report on Thursday, February 3rd. MKM Partners reaffirmed a “hold” rating and set a C$6.50 price objective (up from C$6.00) on shares of Aurora Cannabis in a research note on Friday, February 11th. Finally, Piper Sandler reaffirmed a “hold” rating and set a C$7.00 price objective (up from C$5.00) on shares of Aurora Cannabis in a research note on Friday, February 11th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat, Aurora Cannabis currently has an average rating of “Hold” and an average price target of C$6.11.

ACB traded down C$0.04 on Monday, reaching C$3.86. The company had a trading volume of 1,543,714 shares, compared to its average volume of 1,784,323. Aurora Cannabis has a one year low of C$3.58 and a one year high of C$12.88. The company has a current ratio of 4.92, a quick ratio of 3.13 and a debt-to-equity ratio of 21.20. The company has a market capitalization of C$829.02 million and a P/E ratio of -1.99. The company has a fifty day moving average of C$4.47 and a 200-day moving average of C$6.43.

Aurora Cannabis (TSE:ACBGet Rating) last issued its quarterly earnings results on Thursday, February 10th. The company reported C($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.21) by C($0.32). The business had revenue of C$68.42 million for the quarter, compared to the consensus estimate of C$57.65 million. Research analysts predict that Aurora Cannabis will post -0.8 EPS for the current year.

In other news, Senior Officer Andre Jerome sold 6,916 shares of the stock in a transaction that occurred on Friday, February 18th. The shares were sold at an average price of C$5.31, for a total value of C$36,719.81. Following the completion of the sale, the insider now directly owns 31,674 shares of the company’s stock, valued at C$168,169.94.

Aurora Cannabis Company Profile (Get Rating)

Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.

Further Reading

Analyst Recommendations for Aurora Cannabis (TSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with's FREE daily email newsletter.